<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="51.02" right="55.61" top="88.67"><span x0="51.02" y0="88.67" x1="55.61" style="x0: 51.02; x1: 53.29; y0: 88.67; y1: 92.75; width: 2.27; font-size: 4.08; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">28</span><span x0="58.11" y0="85.6" x1="327.18" style="x0: 58.11; x1: 59.93; y0: 85.6; y1: 92.6; width: 1.82; font-size: 7.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">IPPPR Background Paper 5 &#8212; &#8220;Access to Vaccines, Therapeutics, and Diagnostics.&#8221;</span></div><div left="51.02" right="55.66" top="77.43"><span x0="51.02" y0="77.43" x1="55.66" style="x0: 51.02; x1: 53.29; y0: 77.43; y1: 81.51; width: 2.27; font-size: 4.08; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">29</span><span x0="58.11" y0="74.37" x1="563.23" style="x0: 58.11; x1: 62.0; y0: 74.37; y1: 81.37; width: 3.89; font-size: 7.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">For instance, CEPI could support development and technology transfer of a yellow fever mRNA vaccine, which would set up a new manufacturing plant with a potential commercial product in the inter-pandemic period but prepared to manufacture mRNA-based vaccines during a pandemic. UNICEF could support </span></div><div left="86.46" right="564.01" top="760.96"><span x0="86.46" y0="760.96" x1="564.01" style="x0: 86.46; x1: 88.86; y0: 760.96; y1: 770.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">iii. But it has also shown the drawbacks of waiting for a crisis to occur. The current system &#8212; under a loose coordinating mechanism within ACT-A &#8212; lacks upfront financing and is not speedy enough. A year on, it remains significantly underfunded, which has hampered progress in purchasing and deploying medical countermeasures to those in need.</span></div><div left="86.46" right="564.04" top="697.96"><span x0="86.46" y0="697.96" x1="564.04" style="x0: 86.46; x1: 88.86; y0: 697.96; y1: 707.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">iv. Further, as also observed by the IPPPR, ACT-A is seen by countries and civil society as supply-driven and not inclusive enough, with large donor countries and institutions having an asymmetric influence on decision-making</span><span x0="189.39" y0="677.14" x1="195.94" style="x0: 189.39; x1: 192.63; y0: 677.14; y1: 682.97; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">28</span><span x0="196.02" y0="672.76" x1="534.86" style="x0: 196.02; x1: 198.8; y0: 672.76; y1: 682.76; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">, and some parts of the world opting for regional pooling as an alternative.</span></div><div left="72.29" right="82.76" top="647.56"><span x0="72.29" y0="647.56" x1="82.76" style="x0: 72.29; x1: 77.11; y0: 647.56; y1: 657.56; width: 4.82; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">c. </span><span x0="86.46" y0="647.56" x1="564.28" style="x0: 86.46; x1: 96.46; y0: 647.56; y1: 657.56; width: 10.0; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Black;">We should learn from the COVID-19 experience and develop a permanent, scaled-up and tightly networked ecosystem of partners </span><span x0="252.58" y0="634.96" x1="538.34" style="x0: 252.58; x1: 262.58; y0: 634.96; y1: 644.96; width: 10.0; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">&#8212; public, private and philanthropic &#8212; to enable the following: </span></div><div left="86.46" right="564.05" top="609.76"><span x0="86.46" y0="609.76" x1="564.05" style="x0: 86.46; x1: 88.86; y0: 609.76; y1: 619.76; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. Accelerating innovation processes and facilitating the development of candidates and platforms to the regulatory end-point</span></div><div left="86.46" right="393.8" top="571.96"><span x0="86.46" y0="571.96" x1="393.8" style="x0: 86.46; x1: 88.86; y0: 571.96; y1: 581.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">ii. Achieving adequate global scale in manufacturing, including by: </span></div><div left="100.63" right="564.08" top="546.36"><span x0="100.63" y0="546.36" x1="564.08" style="x0: 100.63; x1: 106.19; y0: 546.36; y1: 556.36; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">1. Having a full view of global manufacturing capabilities to know which ones can be activated rapidly at any point </span></div><div left="100.64" right="564.01" top="508.16"><span x0="100.64" y0="508.16" x1="564.01" style="x0: 100.64; x1: 106.2; y0: 508.16; y1: 518.16; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">2. Enabling adequate global diversification of facilities to ensure supply resilience in a pandemic, and supporting technology transfer to countries or regions to build up manufacturing capabilities</span></div><div left="100.64" right="564.03" top="469.96"><span x0="100.64" y0="469.96" x1="564.03" style="x0: 100.64; x1: 106.2; y0: 469.96; y1: 479.96; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">3. Implementing a coherent strategy of push and pull contracts to support the business case for the needed ever-warm global manufacturing capacity, including its use in inter-pandemic periods to meet continuing needs</span><span x0="219.2" y0="449.14" x1="225.83" style="x0: 219.2; x1: 222.44; y0: 449.14; y1: 454.97; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">29</span></div><div left="86.46" right="564.07" top="419.56"><span x0="86.46" y0="419.56" x1="564.07" style="x0: 86.46; x1: 88.86; y0: 419.56; y1: 429.56; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">iii. Focusing on last-mile delivery, including investments in critical domestic supply chains in developing countries for delivering vaccines and other medical supplies</span></div><div left="72.28" right="563.99" top="381.76"><span x0="72.28" y0="381.76" x1="563.99" style="x0: 72.28; x1: 78.39; y0: 381.76; y1: 391.76; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">d. Significantly enhanced, continuous and pre-arranged funding is required to enable this end-to-end supply chain ecosystem and avoid huge gaps in access to medical countermeasures in a pandemic. </span><span x0="503.12" y0="369.16" x1="564.21" style="x0: 503.12; x1: 513.12; y0: 369.16; y1: 379.16; width: 10.0; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Black;">We propose that this be financed through a new Global Health Threats Fund (Proposal 2 in Section C), which will provide enhanced and more predictable funding to complement existing global health intermediaries.</span></div><div left="51.02" right="66.43" top="317.96"><span x0="51.02" y0="317.96" x1="66.43" style="x0: 51.02; x1: 56.58; y0: 317.96; y1: 327.96; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">37. </span><span x0="72.28" y0="317.96" x1="564.2" style="x0: 72.28; x1: 82.28; y0: 317.96; y1: 327.96; width: 10.0; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Black;">We also need regulatory reforms to speed up time from development of these medical countermeasures to manufacturing.</span></div><div left="72.28" right="561.26" top="278.96"><span x0="72.28" y0="278.96" x1="561.26" style="x0: 72.28; x1: 77.47; y0: 278.96; y1: 288.96; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. Enable trials to be conducted across pharmaceutical companies and for multi-vaccine platform technologies.</span></div><div left="72.28" right="564.06" top="252.96"><span x0="72.28" y0="252.96" x1="564.06" style="x0: 72.28; x1: 78.39; y0: 252.96; y1: 262.96; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. Allow products that are developed in one country to be able to rapidly undergo regulatory assessment internationally.</span></div><div left="72.28" right="425.15" top="213.96"><span x0="72.28" y0="213.96" x1="425.15" style="x0: 72.28; x1: 77.1; y0: 213.96; y1: 223.96; width: 4.82; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">c. Formalize process for adaptive regulatory reviews in emergency situations.</span></div><div left="86.45" right="564.09" top="187.96"><span x0="86.45" y0="187.96" x1="564.09" style="x0: 86.45; x1: 88.85; y0: 187.96; y1: 197.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. Governments should also consider setting up commissions to be able to make decisions rapidly on novel study and trial methods &#8212; based on both scientific and ethical foundations &#8212; in the effort to speed up availability of medical countermeasures.</span></div></body></html>